Administration of granulocyte colony-stimulating factor from day 7 after autologous bone marrow transplantation: effects on neutropenia and duration of hospitalization.
G-CSF (5 mg/kg/day Filgrastim) was administered from day 7 after autologous bone marrow transplantation (ABMT) in a series of 17 patients treated for multiple myeloma or non-Hodgkin's lymphoma. In comparison with retrospective controls receiving ABMT without G-CSF and matched for age, underlying disease, disease status at ABMT, number of CFU-GM/kg reinfused, conditioning regimen and number and type of chemotherapy courses prior to ABMT, the duration of neutropenia, intravenous antibiotics and hospitalization was significantly reduced in the G-CSF group (p < 0.001). Delaying the administration of G-CSF after ABMT is an interesting possibility which merits further exploration in prospective randomized studies.
Moreau
P
P
Department of Haematology, CHU Hôtel-Dieu, Nantes, France.
Le Tortorec
S
S
Mahé
B
B
Legros
L
L
Milpied
N
N
Harousseau
J L
JL
D000328:Adult; D016026:Bone Marrow Transplantation; D016022:Case-Control Studies; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006403:Hematologic Tests; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D007902:Length of Stay; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D009503:Neutropenia / Q000188:drug therapy*; D012189:Retrospective Studies; D014182:Transplantation, Autologous
D016179:Granulocyte Colony-Stimulating Factor